Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).

Article  CAS  PubMed  Google Scholar 

Ascierto, P. A. et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 5, 187–194 (2019).

Article  PubMed  Google Scholar 

Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).

Article  CAS  PubMed  Google Scholar 

Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24–34 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Knight, A., Karapetyan, L. & Kirkwood, J. M. Immunotherapy in melanoma: recent advances and future directions. Cancers 15, 1106 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wallace, D. C. Mitochondria and cancer. Nat. Rev. Cancer 12, 685–698 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zong, W. X., Rabinowitz, J. D. & White, E. Mitochondria and cancer. Mol. Cell 61, 667–676 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salhi, A. et al. Oxidative phosphorylation promotes primary melanoma invasion. Am. J. Pathol. 190, 1108–1117 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andrzejewski, S. et al. PGC-1α promotes breast cancer metastasis and confers bioenergetic flexibility against metabolic drugs. Cell Metab. 26, 778–787.e5 (2017).

Article  CAS  PubMed  Google Scholar 

El-Botty, R. et al. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. Nat. Commun. 14, 4221 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao, R.-Z., Jiang, S., Zhang, L. & Yu, Z.-B. Mitochondrial electron transport chain, ROS generation and uncoupling (review). Int. J. Mol. Med. 44, 3–15 (2019).

CAS  PubMed  PubMed Central  Google Scholar 

Luna Yolba, R. et al. EVT-701 is a novel selective and safe mitochondrial complex 1 inhibitor with potent anti-tumor activity in models of solid cancers. Pharmacol. Res. Perspect. 9, e00854 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Naguib, A. et al. Mitochondrial complex I inhibitors expose a vulnerability for selective killing of Pten-null cells. Cell Rep. 23, 58–67 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshida, J. et al. Mitochondrial complex I inhibitors suppress tumor growth through concomitant acidification of the intra- and extracellular environment. iScience 24, 103497 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24, 1036–1046 (2018).

Article  CAS  PubMed  Google Scholar 

Vasan, K. & Chandel, N. S. Molecular and cellular mechanisms underlying the failure of mitochondrial metabolism drugs in cancer clinical trials. J. Clin. Invest. 134, e176736 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Yap, T. A. et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat. Med. 29, 115–126 (2023).

Article  CAS  PubMed  Google Scholar 

Janku, F. et al. First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer. Invest. New Drugs 39, 1348–1356 (2021).

Article  CAS  PubMed  Google Scholar 

Lazarou, M., Thorburn, D. R., Ryan, M. T. & McKenzie, M. Assembly of mitochondrial complex I and defects in disease. Biochim. Biophys. Acta 1793, 78–88 (2009).

Article  CAS  PubMed  Google Scholar 

Stroud, D. A. et al. Accessory subunits are integral for assembly and function of human mitochondrial complex I. Nature 538, 123–126 (2016).

Article  CAS  PubMed  Google Scholar 

Spinazzi, M., Casarin, A., Pertegato, V., Salviati, L. & Angelini, C. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nat. Protoc. 7, 1235–1246 (2012).

Article  CAS  PubMed  Google Scholar 

Balsa, E. et al. Defective NADPH production in mitochondrial disease complex I causes inflammation and cell death. Nat. Commun. 11, 2714 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Enns, G. M. et al. Degree of glutathione deficiency and redox imbalance depend on subtype of mitochondrial disease and clinical status. PLoS ONE 9, e100001 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Jhunjhunwala, S., Hammer, C. & Delamarre, L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat. Rev. Cancer 21, 298–312 (2021).

Article  CAS  PubMed  Google Scholar 

Yang, K., Halima, A. & Chan, T. A. Antigen presentation in cancer—mechanisms and clinical implications for immunotherapy. Nat. Rev. Clin. Oncol. 20, 604–623 (2023).

Article  CAS  PubMed  Google Scholar 

Leone, P. et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J. Natl Cancer Inst. 105, 1172–1187 (2013).

Article  CAS  PubMed  Google Scholar 

Meissner, T. B. et al. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc. Natl Acad. Sci. USA 107, 13794–13799 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moussa, P., Marton, J., Vidal, S. M. & Fodil-Cornu, N. Genetic dissection of NK cell responses. Front. Immunol. 3, 425 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Yoshihama, S. et al. NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. Sci. Rep. 11, 3258 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshihama, S. et al. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc. Natl Acad. Sci. USA 113, 5999–6004 (2016).